Qinghai Biotech Pharmaceutical Group Limited Receivables

The latest receivables for 0876.HK is $270M as of June 2026. That compares with $98M in the prior-year period — up 173.4% year over year. Investors often review this figure alongside Qinghai Biotech Pharmaceutical Group Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, 0876.HK's receivables moved from $98M to $270M — a 173.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Qinghai Biotech Pharmaceutical Group Limited's operating scale or balance-sheet position.

A receivables figure of $270M for 0876.HK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 0876.HK's receivables ($270M), review year-over-year change from $98M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.